Sensitive and Reliable Results

Concentrations of ctDNA vary among tumor types and among individuals. This variability in ctDNA concentration creates the need for a highly sensitive technology to detect genomic mutations at lower concentrations. The Follow It assay detects mutations down to 0.1% variant allele frequency*.   

Follow It detects common, clinically relevant genomic alterations in solid tumor samples, including single-base substitutions (SNVs), small deletions, and insertions (up to 24bp). It evaluates the mutation status of tumor DNA at 337 hotspots and 26 exons in 37 known cancer-associated genes simultaneously.

Follow It targets genes for non-small cell lung cancer, melanoma, colorectal cancer, GIST, basal cell, breast cancer, endometrial, and other solid tumor cancers.

GenePosition
AKT1E17
ALK T1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275, Y1278
ARL702, V716, S741, W742, Q784, H875, F877, T878, M896
BRAFQ201, G464, G466, F468, G469, Y472, D594, F595, G596, L597, V600, K601, part of Exon15 (V600-M620), G606
CCNEAmplification
CTNNB1D32, S33, G34, I35, H36, S37, T41, S45
DDR2L239, I638, S768
DICER1D1705-D1709, G1809, D1810-E1813
EGFR R108, A289, S492, P596, G598, Exon18, Exon19, Exon20, Exon21, & Amplification
ERBB2G309, S310, K753, L755, I767, D769, Exon20, & Amplification
ESR1K303, E380, S463, V534, P535, L536, Y537, D538
FGFR1N546, K656 + Amplification
FGFR2 S252, P253, W290, A315, S372, Y375, C382, N549, K659, E731, E777, & Amplification
FGFR3R248, S249, G370, S371, Y373, G380, A391, K650
FOXL2C134
GNA11Q209
GNAQQ209
GNASR201
HRASG12, G13, Q61
IDH1R132
IDH2R140, R172
KITS476, Y553, W557,, V559, V560, L576, K642, V654, T670, D816, D820, N822, Y823, A829, Exon9, Exon11, Exon13, & Amplification
KRASK5, A11, G12, G13, L19, Q22, A59, G60, Q61, K117, A146, & Amplification
MAP2K1(MEK1)F53, Q56, K57, K59, V60, D67, I103, I111, C121, N122, P124, P387
MAP2K2(MEK2)F57, Q60, K61, L119, H123, G132
MET T1010, V1112, H1112, G1181, L1213, D1246, Y1248, Y1253, Exon13, Exon14, Exon14 (-50 to+25), Exon18, Amplification
NRASG12, G13, A59, G60, Q61, K117, A146
NTRK1F589, G595, G667
NTRK3G623, G696
PDGFRAR560-E571, P577, N659, L839-Y849, D842
PIK3CAR88, C90, R93, P104, G106, N107, R108, K111, R115, N345, R357, G364, E365, Exon6 [start to P377], C420, E453, P539, E542, E545, Q546, D549, E970, E978, M1043, N1044, A1046, H1047, G1049, & Amplification
POLEExons 9-14 (P286R, M295R, S297F, F367S, D368Y, V411L, L424I, M444K, A456P, S459F)
PTCH1W844, G1093
PTENA126, G129, R130, R173, R233, K254-K267
RETG533, K603, C609, C611, C618, C620, C630, D631, C634, G691, E768, L790, Y791, V804, Y806, A883, R886, S904, M918, A919, Exon10, Exon 13, Exon15
ROS1S1986, G2032, L2026
STK11Q37, P281
TP53Exon4, Exon5, Exon6, Exon7, Exon8, Exon9
MSI21 Loci
Breast Cancer
Biomarkers detected by Plasma Follow It®Available FDA Approved TherapyAMP/ASCO/CAP Tier*Resistance
AKT1 E17KNoIBNo
ERBB2 amplificationYesIANo
ERBB2 oncogenic mutationsNoIBNo
ESR1 oncogenic mutationsNoIBNo
FGFR1 amplificationNoIICNo
PIK3CA oncogenic mutationsYesIANo
MSI-HYesIANo
Colorectal Cancer
Biomarkers detected by Plasma Follow It®Available FDA Approved TherapyAMP/ASCO/CAP Tier*Resistance
BRAF V600EYesIANo
ERBB2 AmplificationYesIA/IBYes
KRAS wild typeYesIANo
KRAS and NRAS wild-typeYesIANo
KRAS and NRAS oncogenic mutationsYesIAYes
MSIYesIANo
Endometrial Cancer (Metastatic Cases)
Biomarkers detected by Plasma Follow It®Available FDA Approved TherapyAMP/ASCO/CAP Tier*Resistance
AKT1 E17KNoIBNo
MSI/MMRdYesIANo
POLENoNoNo
Gastric
Biomarkers detected by Plasma Follow It®Available FDA Approved TherapyAMP/ASCO/CAP Tier*Resistance
ERBB2 amplificationYesIANo
MSIYesIANo
GIST
Biomarkers detected by Plasma Follow It®Available FDA Approved TherapyAMP/ASCO/CAP Tier*Resistance
KIT oncogenic mutationsYesIA/IIDNo
KIT A829, D816, D820, N822, T670, V654, Y823YesIIDYes
KIT V654YesIIDYes
PDGFRA oncogenic mutationsYesIANo
PDGFRA D842YesIAYes
NSCLC
Biomarkers detected by Plasma Follow It®Available FDA Approved TherapyAMP/ASCO/CAP Tier*Resistance
ALK oncogenic mutationsYesIA/IIDYes
BRAF V600EYesIANo
EGFR G719 (exon 18), exon 19 deletions, S768I (exon 20), L858R, L861Q (exon21)YesIANo
EGFR exon 19 deletions, L858R (exon 21)YesIANo
EGFR exon 20 insertion, T790M (exon 20)YesIAYes
EGFR T790M (exon 20), L858R (exon 21)YesIANo
EGFR C797, L718, L792, G796YesIIDYes
EGFR exon 20 insertionYesIANo
EGFR exon 18 indelNoIBNo
EGFR exon 19 insertionNoIBNo
EGFR exon 19 & 20 insertion, L747NoIIDNo
ERBB2 oncogenic mutationsYesIANo
KRAS G12CYesIANo
MAP2K1 oncogenic mutationsNoIBNo
MET exon 14 skippingYesIANo
MET amplificationYesIA/IIDYes
Melanoma
Biomarkers detected by Plasma Follow It®Available FDA Approved TherapyAMP/ASCO/CAP Tier*Resistance
BRAF V600YesIANo
BRAF V600EYesIANo
BRAF V600KYesIANo
BRAF L597, V601NoIBNo
KIT oncogenic mutationsYesIANo
MAP2K1 oncogenic mutationsNoIBNo
NRAS oncogenic mutationsNoIB/IIDNo
Urothelial Cancer
Biomarkers detected by Plasma Follow It®Available FDA Approved TherapyAMP/ASCO/CAP Tier*Resistance
FGFR3 R248C, S249C, G370C, Y373CYesIANo
FGFR3 S371C, G380R, K650NoIBNo
HRAS oncogenic mutuationsNoIBNo
All Solid Tumors
Biomarkers detected by Plasma Follow It®Available FDA Approved TherapyAMP/ASCO/CAP Tier*Resistance
BRAF G464, G469, L597, K601NoIIDNo
FGFR1, FGFR2, FGFR3 oncogenic mutationsNoIIDNo
KRAS oncogenic mutationsNoIIDNo
Microsatellite Instability-High (MSI-H)YesIANo
NTRK1 and NTRK3 mutationsYesIAYes
NTRK1 G595RYesIIDYes
PTEN oncogenic mutationsNoIIDNo
Genes38
Hotspots337
Exons26
Turnaround Time3-5 days
Mutation typesSNVs, deletions and insertions (up to 24bp), CNVs
Sample TypeBlood
Sample Requirement2 x 10 mL of blood in Streck tubes

Benefits

Relevant Results

Target mutations and other genomic aberrations commonly associated with prevalent solid tumors.

End to End Solution

Single Integrated assay, analysis, and reporting platform streamlines assay and results reporting workflow.

Comprehensive Reports

Review detailed interpretations, current treatment options, and available clinical trials.

Cost-Effective

Targeted amplicon-based technology provides an economical alternative to single-gene testing or hybrid capture NGS assays.

Minimally Invasive

A minimally invasive option for clinical research, Follow It can also be used to observe cancer progression or detection of treatment resistance.

Accreditation

All Imagia Canexia Health’s assays and software are developed in our CLIA, CAP, CDPH and DAP accredited laboratory.

Recent Resources

View Other Solutions

Tissue

Imagia Canexia Health’s Find It & Fusions panels detect mutations and gene fusion events in solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.

Learn About Tissue Assays

Imagia Canexia Health Insights Platform

Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.

Learn About Our Reports

Comprehensive Reports, Right From Your Lab

Perform cancer genomic profiling, right from your laboratory. From mutation identification to auto-generated clinical reports, Imagia Canexia Health’s proprietary platform puts the control back in your hands.

Learn More

Canadian Access to Follow It

Through an initiative called Project ACTT, Imagia Canexia Health is providing access to Follow It, our blood-based circulating tumor DNA (ctDNA) next-generation sequencing (NGS) hotspot panel. Project ACTT is currently open to patients throughout Canada via oncologist referral.

Learn More